

REMARKS


Claims 21-26 and 35 are pending in the application. With entry of the instant amendment, claims 21 and 22 have been amended. The amendments add no new matter and are supported in the specification as filed. Claim 21 has been amended to recite that the xenograft is allowed to grow for a sufficient time to permit the detection of a tumor or the detection of metastatic prostate cancer cells. Support can be found, e.g., in claims 9, 12, and 17 as originally filed.

Applicants thank the Examiner for the interview on May 31, 2005 in which the rejection under 35 U.S.C. § 112, second paragraph applied to claim 26 was discussed. The Examiner agreed to withdraw this rejection. The Examiner also raised a new issue relating to claim 21. The issue involves incorporating an element into claim 21 relating to progression of the xenograft. Applicants agreed to provide such an amendment in order to expedite prosecution. Applicants believe that the amendment to claim 21 addresses this issue.

With regard to the recommended change to claim 22, the amendment to claim 22 provides the requested clarification.

Applicants believe all claims now pending in this Application are in condition for allowance. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,



Jean M. Lockyer
Reg. No. 44,879

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JML:jml
60497431 v1